Evotec SE reported earnings results for the third quarter and nine months ended September 30, 2025. For the third quarter, the company reported sales was EUR 163.89 million compared to EUR 184.89 million a year ago. Net loss was EUR 43.09 million compared to EUR 39.63 million a year ago. Basic loss per share from continuing operations was EUR 0.24 compared to EUR 0.22 a year ago. Diluted loss per share from continuing operations was EUR 0.24 compared to EUR 0.22 a year ago.
For the nine months, sales was EUR 535.1 million compared to EUR 575.74 million a year ago. Net loss was EUR 118.14 million compared to EUR 155.24 million a year ago. Basic loss per share from continuing operations was EUR 0.67 compared to EUR 0.88 a year ago. Diluted loss per share from continuing operations was EUR 0.67 compared to EUR 0.88 a year ago.
Evotec SE is a Germany-based drug discovery and development company. The company is engaged in development of new pharmaceutical products through research alliances and development partnerships with pharmaceutical and biotechnology companies, academic institutions, patient organizations and venture capital companies. The drug discovery solutions are provided in the form of fee-for-service work, integrated drug discovery alliances, development partnerships, licensing of drug candidates and consulting arrangements. Evotec SE operates in a number of areas, including neuroscience, diabetes and complications of diabetes, pain and inflammation, oncology, infectious diseases, respiratory diseases and fibrosis. Its pipeline covers a range of therapeutic areas, such as CNS Insomnia, Chronic cough, immunology & inflammation, womenâs health endometriosis, nephrology, dermatological diseases, fibrotic disease and antiviral, among others.
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
